Figure 5.
Schematic illustration on the key production process of the IVT mRNA and its lipid-based formulation. (1) Once the genome of a pathogen has been revealed, a sequence for the target antigen is designed and inserted into a plasmid DNA construct. (2) Plasmid DNA is transcribed into mRNA by bacteriophage polymerases in vitro and (3) mRNA transcripts are purified with high-performance liquid chromatography (HPLC) to remove contaminants and reactants. (4) Purified mRNA is mixed with lipids in a microfluidic mixer to form lipid nanoparticles.